Ipsen SA - Company Profile
Powered by 
All the sales intelligence you need on Ipsen SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ipsen SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ipsen SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ipsen SA (Ipsen) is a specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company products include Somatuline, Cabometyx, Onivyde, Decapeptyl, and Tazverik. The company develops and commercializes novel medicines for cancer, neuroscience, and rare diseases; and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals. The company operates its research and development facilities in Paris-Saclay, France; London, the UK; and Cambridge, the US. It offers products in Europe, North America, and rest of the world. Ipsen is headquartered in Boulogne-Billancourt, Ile-de-France, France.
Headquarters
France
Address
70 rue Balard, Paris, Ile-de-France, 75015
Website
www.ipsen.com
Telephone
33 1 58335000
No of Employees
5,535
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IPN (EPA)
Revenue (2024)
$4.4B
9.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
28.2%
(2024 vs 2023)
Market Cap*
$15.5B
Net Profit Margin (2024)
XYZ
16.6%
(2024 vs 2023)
* As of and is in US$
Ipsen SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Somatuline |
| Specialty Care: | Decapeptyl |
| Oncology: | Iqirvo |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In July, the company acquired Memo Therapeutics AG, a biotech company. |
| 2026 | Contracts/Agreements | In June, the company signed an agreement to acquire Kartos Therapeutics, a biopharmaceutical company. |
| 2026 | Regulatory Approval | In April, the company received approval from the European Commission for Ojemda (tovorafenib) as monotherapy for the treatment of patients with pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. |
Competitor Comparison
| Key Parameters | Ipsen SA | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United States of America | United Kingdom | Switzerland |
| City | Paris | Rahway | New York City | Cambridge | Basel |
| State/Province | Ile-de-France | New Jersey | New York | Cambridgeshire | Basel-Stadt |
| No. of Employees | 5,535 | 75,000 | 75,000 | 96,100 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marc de Garidel | Chairman | Executive Board | 2016 | 68 |
| David Loew | Director; Chief Executive Officer | Executive Board | 2020 | 59 |
| Aymeric Le Chatelier | Chief Financial Officer; Executive Vice President | Senior Management | 2014 | - |
| Sandra Silvestri | Chief Medical Officer - Executive Vice President | Senior Management | 2023 | - |
| Philippe Lopes-Fernandes | Executive Vice President; Chief Business Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer